INOZYME PHARMA, INC. Proceeds from Common Stock Issued
INOZYME PHARMA, INC. reported Proceeds from Common Stock Issued of $228.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-05-14
- INOZYME PHARMA, INC. proceeds from issuance of common stock for the quarter ending 2025-03-31 was $228.00K.
- INOZYME PHARMA, INC. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $81.00K.
- INOZYME PHARMA, INC. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $10.44M, a 84.99% decline year-over-year.
- INOZYME PHARMA, INC. proceeds from issuance of common stock for the quarter ending 2024-06-30 was $0.00.
- INOZYME PHARMA, INC. proceeds from issuance of common stock for fiscal 2024 was $10.52M, a 87.72% decline from fiscal 2023.
- INOZYME PHARMA, INC. proceeds from issuance of common stock for fiscal 2023 was $85.65M, a 52.57% increase from fiscal 2022.
- INOZYME PHARMA, INC. proceeds from issuance of common stock for fiscal 2022 was $56.14M.
- INOZYME PHARMA, INC. proceeds from issuance of common stock for fiscal 2021 was $0.00.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2025-03-31 | $228.00K 10-Q · filed 2025-05-14 | $309.00K derived: sum of 2 quarters · filed 2025-05-14 | $10.75M derived: sum of 3 quarters · filed 2025-05-14 | $10.75M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $10.52M derived: sum of 2 quarters · filed 2025-03-10 | $10.52M derived: sum of 3 quarters · filed 2025-03-10 | $10.52M 10-K · filed 2025-03-10 | |
| 2024-09-30 | $10.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $10.44M derived: sum of 2 quarters · filed 2024-11-05 | $10.44M 10-Q · filed 2024-11-05 | $10.44M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | -$2.00K derived: sum of 3 quarters · filed 2025-05-14 | $69.56M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | -$2.00K derived: sum of 2 quarters · filed 2025-05-14 | $69.56M derived: sum of 3 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $69.56M derived: sum of 2 quarters · filed 2025-03-10 | $85.65M 10-K · filed 2025-03-10 | ||
| 2023-09-30 | $69.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $85.65M 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | $16.09M 10-Q · filed 2024-08-06 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$42.00K derived: sum of 2 quarters · filed 2024-03-12 | $56.14M 10-K · filed 2024-03-12 | ||
| 2022-09-30 | -$42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $56.14M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $56.18M 10-Q · filed 2023-08-08 | ||||
| 2022-04-19 | $68.30M 10-Q · filed 2022-08-15 | ||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-22 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | ||||
| 2020-07-30 | $115.90M 10-K · filed 2022-03-15 |